USANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
USANA Health Sciences Inc. (USNA) PT Raised to $126 at Roth Capital
February 10, 2021 7:12 AM ESTRoth Capital analyst David Bain raised the price target on USANA Health Sciences Inc. (NYSE: USNA) to $126.00 (from $107.00) while maintaining a Buy rating.
The analyst comments "Following a 7%/~24% revenue/EBITDA beat versus consensus, we raise our CY21/CY22 estimates and target price.... More
USANA Health Sciences (USNA) Tops Q4 EPS by 44c, Offers Guidance
February 9, 2021 4:20 PM ESTUSANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.87, $0.44 better than the analyst estimate of $1.43. Revenue for the quarter came in at $310.5 million versus the consensus estimate of $291.54 million.
GUIDANCE:
USANA Health Sciences sees FY2021 EPS of $6.00-$6.45, versus the... More
